Type 1 Diabetes TrialNet is an international network of researchers who are exploring ways to prevent, delay and reverse the progression of type 1 diabetes.

An international approach to treating diabetes

TrialNet was established in response to the US Surgeon General’s report Healthy People 2010: understanding and improving health. This report identified diabetes as a national health objective for the US.

One recommendation of the resulting strategic plan was to conduct clinical trials to prevent type 1 diabetes. 

TrialNet is now conducting clinical trials with researchers from 18 centres around the world, in addition to more than 150 medical centres and physician offices.

The institute and TrialNet diabetes trials

Clinician scientist Dr John Wentworth is a director of one of these international TrialNet centres, charged with designing and undertaking clinical trials to prevent T1D via a network of collaborative sites in Australia and New Zealand.

As principle investigator, he is responsible for the Natural History Study and Oral Insulin Study in subjects at risk for new onset type 1 diabetes.